July 1 Oncology Update: 10 Key Changes and New Therapies for Seven Cancers

As of July 1, a new reimbursement list introduces 10 significant changes for cancer patients, expanding access to targeted therapies and immunotherapy for seven specific types of malignancies across Poland.

Expanded Treatment Options for Cancer Patients

The July 1 reimbursement list brings 10 vital changes to oncology care. While lung cancer patients see the most significant updates, new treatment pathways are now available for six other types of cancer. Physicians emphasize that these reimbursements allow for more precise, personalized therapy tailored to the individual patient.

For many patients, this update provides access to previously non-reimbursed therapies. Increasingly, the selection of treatment is dictated by the results of molecular diagnostic testing.

Lung Cancer: A Major Focus of the New List

Patients with lung cancer have gained the most from the latest updates, with four new reimbursed therapies approved for various stages of the disease, from pre-operative preparation to post-surgical treatment and advanced disease management.

A critical shift is the expansion of perioperative treatment. Dr. Magdalena Knetki-Wróblewska of the National Institute of Oncology notes that integrating oncology and thoracic surgery significantly reduces the risk of recurrence and cancer-related mortality. Estimates suggest these changes could benefit approximately 40 percent of lung cancer patients.

The Role of Molecular Diagnostics in Targeted Therapy

Unlike historical approaches where patients with the same diagnosis received identical care, treatment today is increasingly guided by molecular profiling. This biological understanding of the tumor drives the inclusion of various immunotherapies and targeted agents on the current list, intended for patients meeting specific medical criteria.

New Reimbursements Across Seven Cancer Types

The updated list provides new treatment options for a range of malignancies. Depending on the case, this includes first-time access to modern immunotherapy, expanded drug programs, or subsequent treatment lines for patients who failed previous therapies.

Key developments include four new lung cancer therapies, initial-line immunotherapy for colon cancer, combined immunotherapy for hepatocellular carcinoma, and broader access to immunotherapy for endometrial cancer. Additionally, new hormonal treatments for prostate cancer, second-line options for multiple myeloma, and innovative therapies for nasopharyngeal carcinoma are now covered.

Immunotherapy and Rare Cancers

The expansion of immunotherapy represents a major shift in cancer care, utilizing the body’s immune system to combat tumors. Patients with colon, endometrial, and hepatocellular cancers are among those benefiting from these new programs, often starting from the first line of treatment.

Professor Lucjan Wyrwicz of the National Institute of Oncology emphasizes that molecular profiles are becoming as important as tumor location in determining treatment. The list also addresses rare cancers, such as nasopharyngeal carcinoma, while offering better-tailored hormonal and secondary therapies for multiple myeloma and prostate cancer patients.